OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Officer exercised or converted 16K CYTK derivative securities | OQRO

Home
Insider trades
Cytokinetics
Officer exercised or converted 16K CYTK derivative securities

Insider trades

Insider trade

Officer exercised or converted 16K CYTK derivative securities

Traded May 1, 2026 · Filed May 4, 2026

CYTCytokineticsCYTK

16K
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: May 1, 2026
Reporting period: Not applicable
Filed with the SEC: May 4, 2026

OfficerOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001061983-26-000046

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

May 4, 2026, 8:01 PM UTC

Added to OQRO

Oct 6, 2026, 7:14 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

CYTOKINETICS INC

Issuer CIK

1061983

Ticker

CYTK

Reporting person

Andrew Callos

Relationship

Officer

Officer title

EVP, Chief Commercial Officer

Security

Non-Qualified Stock Option (Right to Buy)

Table

Derivative (Table II)

Transaction date

May 1, 2026

Transaction code

Shares / units

15,857

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

Ownership form

Direct

Amendment

Footnotes from the filing

This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant.

Around the same time

Edward M. Md Kaye (Director) sold ~$223K of Cytokinetics

Automatic saleFiled 4mo ago

Andrew CallosEVP, Chief Commercial Officer

Filed 4mo ago

15KShares · @ $23.26

Traded Jun 1 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record

Andrew Callos (EVP, Chief Commercial Officer) sold ~$1.11M of Cytokinetics

Automatic saleFiled 4mo ago